Proton-pump inhibitor - Wikipedia
Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action - ScienceDirect
Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes - Journal of Pharmaceutical Sciences
Pharmacological management of GERD | DDDT
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. - Abstract - Europe PMC
phat-10k_20201231.htm
SEC Filing | Phathom Pharmaceuticals, Inc.
Figure 1 | Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | SpringerLink
Mechanism of Action Proton Pumps Inhibitors - YouTube
The Physiology of the Gastric Parietal Cell | Physiological Reviews
Vonoprazan-based therapy for <i>Helicobacter pylori</i> eradication: experience and clinical evidence. - Abstract - Europe PMC
Vonoprazan Fumarate | New Drug Approvals
Potassium-Competitive Acid Blocker: Novel Class of Anti- Acid Drug
Simplified schematic description: differences between 'conventional'... | Download Scientific Diagram
Pharmaceuticals | Free Full-Text | The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy | HTML
Mode of action of P-CABs as compared with PPIs. The PPIs convert to... | Download Scientific Diagram
Phathom Could See Substantial Upside With 2 Upcoming Phase 3 Readouts (PHAT) | Seeking Alpha
Figure 2 from Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | Semantic Scholar
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases - ScienceDirect
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications | Nature Reviews Gastroenterology & Hepatology
Phathom Could See Substantial Upside With 2 Upcoming Phase 3 Readouts (PHAT) | Seeking Alpha
Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility | Journal of Pharmacology and Experimental Therapeutics
Inhibiting the proton pump: mechanisms, benefits, harms, and questions | BMC Medicine | Full Text
Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020 (NASDAQ:PHAT) | Seeking Alpha
